Lymphoproliferative disease
Conditions
Interventions
experimental group:Infusion Anti - CD99 CAR - T
Sponsors
Affiliated Hospital of Xuzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients or their legal guardians voluntarily participate in and sign informed consent; 2. Male or female patients aged 18-70 (including 18 and 70 years old); 3. The patient was diagnosed as CD99 + lymphoproliferative disease by pathology and histology. At present, the patient has no effective treatment plan, such as chemotherapy or relapse after hematopoietic stem cell transplantation, or the patient voluntarily chooses anti-CD99 car-t as rescue treatment; 4. Patients with CD99 + lymphoproliferative diseases: (1) T-cell proliferative diseases (T-cell LPD); (2) T-cell acute lymphoblastic leukemia (T-ALL); (3) Ewing sarcoma (EWS); (4) Acute myeloid leukemia (AML); (5) The myelodysplastic syndromes (MDS); (6) B-lymphocytic lymphoma / leukemia; (7) Anaplastic large cell lymphoma (ALCL), especially the ALCL positive for anaplastic lymphoma kinase (ALK) and the systemic anaplastic large cell lymphoma (SRL); (8) Precursor T-cell lymphoblastic leukemia / lymphama (t-lbl); (9) Angioimmunoblastic T-cell lymphoma (AITL); (10) Peripheral T-cell lymphoma (PTCL); (11) T-cell acute lymphoblastic leukemia (T-ALL) is another CD99 + lymphoproliferative disease.
Exclusion criteria
Exclusion criteria: 1. Women in pregnancy (positive urine / blood pregnancy test) or lactation; 2. Men or women who have pregnancy plans in the past year; 3. Patients who can't take effective contraceptive measures (condoms or contraceptives, etc.) within one year after enrollment; 4. Patients with uncontrollable infectious diseases within 4 weeks before enrollment; 5. Patients with active hepatitis B / C; 6. HIV infected patients; 7. Patients with serious autoimmune diseases or immunodeficiency diseases; 8. Patients with allergic constitution and allergic to macromolecular biological drugs such as antibodies or cytokines; 9. Patients who participated in other clinical trials within 6 weeks before admission; 10. Patients who systematically used hormone (except those who used inhaled hormone) within 4 weeks before admission; 11. Patients with mental illness; 12. Patients with drug abuse / addiction; 13. According to the judgment of the researcher, the patient has other unsuitable conditions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR;CR;PR; | — |
Secondary
| Measure | Time frame |
|---|---|
| OS;PFS;EFS; | — |
Countries
China
Contacts
Public ContactWei Sang
Affiliated Hospital of Xuzhou Medical University
Outcome results
None listed